Venus Remedies gets patent from Japan for anti-bacterial drug

Disclaimer: Information presented on this site is a guide only. It may not necessarily be correct and is not intended to be taken as financial advice nor has it been prepared with regard to the individual investment needs and objectives or financial situation of any particular person. Stock quotes are believed to be accurate and correctly dated, but does not warrant or guarantee their accuracy or date.
Our site takes no responsibility for any investment decisions based on recommendations provided on website.
Google Adsense Ads are posted on every page of the website so visitors clicking on Ads and going to those links and carrying any financial deal is not at all related to to our website and any financial deal should be done on their own sole responsibility.

Drug firm Venus Remedies today said it has received patent approval from the Japanese health regulator for Vancoplus, which is used in treating bacterial resistance.

The company has received patent grant for Vancoplus from Japan Patent Office (JPO), Venus Remedies said in a statement.

The patent grant for Vancoplus is valid up to February, 2026, the company said, adding that the approval is the company's first in the Japanese market.

The company said it aims to launch Vancoplus in Japan in early 2015. The product is at present available in emerging markets and is under registration in many countries.

"The market size of MRSA in the world accounts for $900 million. Presently, it is growing with CAGR of 4.8%, which is estimated to reach to $1.2 billion by 2017," Venus Remedies said.

The company also intends to out-license Vancoplus to major pharmaceutical players, it added.